Hikma has provided a trading update that sheds fresh light on plans for its delayed Advair generic, as well as revealing some new launches.
Hikma is planning to introduce its US generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) early next year, the firm has outlined as it provided a trading update that offered revised financial forecasts as well as details of two new US generic launches.
In September, Hikma revealed that it had received a further complete response letter from the US Food and Drug Administration...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
